Patient Treatment

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 136 CE courses, most popular
$95Add to cart
Pick Your Courses
Up to 8 CE hours
$50Add to cart
Individual course$20Add to cart
The page below is a sample from the LabCE course Laboratory Evaluation of the Lupus Anticoagulant found in Antiphospholipid Syndrome (APS). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Laboratory Evaluation of the Lupus Anticoagulant found in Antiphospholipid Syndrome (APS) (online CE course)
Patient Treatment

Patients who present with LA and recurrent thrombosis, are candidates for prolonged or indefinite anticoagulant versus patients who present with LA but without thrombosis. Obstetrical complications such as miscarriages may be prevented by prophylactically placing a patient on aspirin and unfractionated heparin. Patients who have LA may be given hydroxychloroquine, which is a drug used in malaria. It has demonstrated prevention of thrombosis in this population. In managing any auto-immune disease, prophylactic therapy is also used during surgery or hospitalization. However, it is important to make sure you do not put the sample at a risk for bleeding.
Many of these patients are placed on low-dose aspirin as a primary prevention, however its efficacy is unproven. Clopidogrel has been shown to be helpful in these patients, and useful if patients are allergic to aspirin.
When patients have a thrombotic event, they may be placed on heparin, and then transitioned to warfarin for long term anticoagulation. They are monitored by the International normalized ratio (INR), and may require an INR in the range of 3.0-4.0 which is higher than the recommendation for venous thrombosis (2.0-3.0) and arterial thrombosis (3.0). Significant and repeated thrombotic events require lifelong anticoagulation.
There is limited information in using the direct oral anticoagulants in this patient population. The drugs at this time do not have an indication for use, so vitamin K antagonists remain the drug of choice. Clinical trials are ongoing to demonstrate efficacy of these drugs in LA patients.